First, chronic hepatitis B treatment pursues a higher goal – HBsAg negative. In the past, there has been a controversy on the issue of stopping medication after the treatment of chronic hepatitis B. It is mostly believed that after the DNA of hepatitis B virus turns negative, the medication will be taken for another year or after the seroconversion of HBeAg/anti-Hbe seroconversion, the medication will be taken for another half a year. Despite this condition, there is still a high relapse rate after stopping medication. For this reason, professionals now propose that, in addition to HBeAg seroconversion, accompanied by the disappearance of HBsAg and the emergence of anti-HBs, before the drug can be discontinued to reduce recurrence. Because HBsAg is positively correlated with intrahepatic cccDNA, it is difficult to remove intrahepatic cccDNA with current treatment. When HBsAg disappears in the serum, it suggests that intrahepatic cccDNA disappears. HBV DNA and cccDNA are consistent. When HBV DNA disappears, cccDNA is still present in the liver. it has been observed that changes in the quantification of HBsAg in the serum can predict the occurrence of durable response rates. Clinical application of interferon regular check HBsAg quantitative can predict its efficacy and discontinuation of durable response prediction of the most sufficient evidence. Second, pregnant women with hepatitis B triple positive, how to reduce infant infection “Viral Hepatitis Prevention and Control Program” for mothers with hepatitis B positive to their infants to implement the “mother-infant combined blocking method”. Through years of clinical observation, there are still a small number of infants infected with hepatitis B virus. It has been studied that 2% to 6% of infants whose mothers are HBsAg(+) are still infected with HBV after combined immunization (hepatitis B vaccine + hepatitis B immune globulin). Further observation shows that the reason for failure is related to the HBV DNA load in the mother’s body, when the HBV DNA load is <106 copies, the rate of HBV infection in infants is 0. When the HBV DNA load is ≥106 copies, the failure of immunization is up to 3.2%, and when the HBV DNA load is ≥107～108 copies, the failure is 6.7～7.6%. For this reason, experts recommend that pregnant women with HBV DNA more than 106 copies in the last 3 months of pregnancy can be treated with antiviral therapy, which can reduce the rate of intrauterine infection, and elective cesarean section can also be considered to prevent vertical transmission.